## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract; no access to full manuscript, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors report synthesis of three benzimidazole compounds containing a benzophenone group, structural characterization using multiple spectroscopic and crystallographic methods, and evaluation of DNA binding properties via UV-vis, photoluminescence spectroscopy, viscosity tests, and molecular docking. They report DNA binding constants (Kb) of 3.0 x 10^4, 7.0 x 10^4, and 3.0 x 10^4 M^-1 for compounds A, B, and C, respectively, and conclude groove binding mode based on UV-vis, ethidium bromide (EB) competitive binding, and viscosity tests. Molecular docking identified compound B as showing the best DNA binding activity, consistent with in vitro results. The authors suggest potential application of these compounds as DNA binding agents in cancer drug research.
- **Visible evidence base** Abstract text only; no experimental details, spectra, crystallographic data, docking parameters, or statistical analyses are provided
- **Missing materials affecting confidence** Full manuscript, experimental procedures, characterization data (FT-IR, NMR, UV-vis, photoluminescence, X-ray crystallography), DNA binding assay protocols, viscosity measurement details, molecular docking methodology and scoring functions, calibration equations, and any statistical error analysis

## Reviewer
- **Overall assessment** The abstract presents a straightforward synthetic and biophysical study with a clear aim, but the evidence base available for review is limited to the abstract alone. The reported DNA binding constants are modest and within a narrow range, and the claim of groove binding mode is plausible but not verifiable from the abstract. The molecular docking result identifying compound B as the best binder is consistent with the in vitro ranking, which is a positive feature. However, the absence of experimental details, error estimates, and comparative analysis with known DNA binding agents limits the strength of the conclusions. The study is of interest to a specialized audience in bioinorganic chemistry and drug design, but the novelty and broader impact are not clearly established from the abstract.
- **Who would be interested in the results, and why** Researchers in medicinal chemistry, bioinorganic chemistry, and nucleic acid biochemistry would be interested in the synthesis and DNA binding evaluation of new benzimidazole-benzophenone hybrids. The work may also appeal to those investigating groove binding small molecules as potential anticancer leads, given the established relevance of DNA binding agents in chemotherapy.
- **Major strengths** The study combines multiple complementary experimental techniques (UV-vis, photoluminescence, viscosity) with computational docking to assess DNA binding, which is a robust approach. The consistency between in vitro ranking and docking results for compound B strengthens the internal validity of the findings. The use of X-ray crystallography for structural determination adds credibility to the compound characterization.
- **Major Concerns**  
  - R1-M1  
  - R1-M2  
  - R1-M3
- **Minor Comments**  
  - R1-m1  
  - R1-m2  
  - R1-m3
- **Technical failings that need to be addressed before the case is established** The abstract does not provide error estimates or standard deviations for the reported binding constants, which are essential for assessing the reliability of the differences between compounds. The claim of groove binding mode is based on indirect evidence (EB competition and viscosity) but no quantitative data or comparative controls are described. The molecular docking methodology is not detailed, including the protein or DNA structure used, scoring function, or validation of docking parameters, which prevents assessment of the reliability of the computational results.
- **Assessment against Nature-style criteria**  
  - Originality: The combination of benzimidazole and benzophenone moieties for DNA binding is not clearly novel, as both scaffolds are well studied in medicinal chemistry. The abstract does not articulate a new mechanistic insight or a unique structural feature that would distinguish this work from prior studies.  
  - Scientific importance: The findings are incremental, reporting moderate binding affinities without evidence of selectivity or functional relevance (e.g., cytotoxicity or cellular activity). The potential for cancer drug research is speculative and not supported by any biological data.  
  - Interdisciplinary readership: The work bridges synthetic chemistry, spectroscopy, and computational biology, but the narrow scope and lack of broader implications limit appeal beyond a specialized audience.  
  - Technical soundness: The use of multiple techniques is commendable, but the abstract lacks sufficient detail to assess the rigor of the experiments, particularly regarding error analysis, controls, and docking validation.  
  - Readability for nonspecialists: The abstract is concise and generally clear, but technical terms and abbreviations (e.g., EB, Kb) are used without definition, which may hinder nonspecialist comprehension.
- **Recommendation posture** Currently not established from the provided evidence. The abstract alone does not provide sufficient detail to support the core claims of binding mode and relative activity. A full manuscript with complete experimental data, error analysis, and docking validation would be required to assess whether the conclusions are justified.

### Major Concerns

- **Concern ID** R1-M1  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Technical soundness  
- **Claim pointer** The authors report DNA binding constants (Kb) of 3.0 x 10^4, 7.0 x 10^4, and 3.0 x 10^4 M^-1 for compounds A, B, and C, respectively.  
- **Evidence pointer** Abstract, location not provided  
- **Concern** The binding constants are reported without any error estimates, standard deviations, or number of replicates. The difference between compound B (7.0 x 10^4) and compounds A and C (both 3.0 x 10^4) is only a factor of approximately 2.3, which may not be statistically significant without error analysis.  
- **Why it matters** The central conclusion that compound B shows the best DNA binding activity depends on the reliability of these values. Without error estimates, the ranking of compounds cannot be considered robust, and the comparison with literature values is not meaningful.  
- **Resolution test** Provide mean values with standard deviations from at least three independent measurements, and report the statistical significance of the differences between compounds (e.g., via t-test or ANOVA).

- **Concern ID** R1-M2  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Technical soundness  
- **Claim pointer** The authors state that UV-vis, EB competitive binding, and viscosity tests showed that the compounds tended to bind to the DNA structure via the groove binding mode.  
- **Evidence pointer** Abstract, location not provided  
- **Concern** The abstract does not provide any quantitative data or comparative controls to support the groove binding mode assignment. EB competitive binding and viscosity tests are indirect methods that require careful interpretation, and the absence of data (e.g., fluorescence quenching percentages, viscosity ratios, or comparison with known intercalators like ethidium bromide) prevents verification of the claim.  
- **Why it matters** The binding mode is a key conclusion of the study and has implications for the potential biological activity of the compounds. An incorrect assignment would undermine the interpretation of the DNA binding results and the proposed relevance to cancer drug research.  
- **Resolution test** Provide representative data for EB competition assays (e.g., Stern-Volmer quenching constants) and viscosity measurements (e.g., relative viscosity vs. compound concentration) with appropriate positive and negative controls (e.g., known groove binder and intercalator).

- **Concern ID** R1-M3  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Technical soundness  
- **Claim pointer** The authors state that molecular docking studies determined that compound B showed the best DNA binding activity, consistent with in vitro studies.  
- **Evidence pointer** Abstract, location not provided  
- **Concern** The abstract does not describe the docking methodology, including the DNA structure used, the docking software, the scoring function, or the validation of the docking protocol. Without these details, the reliability of the docking results cannot be assessed, and the consistency with in vitro data may be coincidental.  
- **Why it matters** Molecular docking is a predictive tool that requires careful setup and validation. If the docking protocol is not robust, the conclusion that compound B is the best binder is not supported, and the agreement with in vitro results cannot be interpreted as confirmation.  
- **Resolution test** Provide full docking parameters, including the DNA structure (PDB ID), software version, scoring function, and a validation step (e.g., redocking of a known ligand or comparison with experimental binding modes). Report docking scores and binding poses for all three compounds.

### Minor Comments

- **Concern ID** R1-m1  
- **Severity** Minor  
- **Axis** Readability  
- **Affected element** Abstract text  
- **Evidence pointer** Abstract, location not provided  
- **Issue** The abstract uses abbreviations such as EB and Kb without defining them at first use.  
- **Required correction** Define EB (ethidium bromide) and Kb (binding constant) in the abstract or provide a brief explanation for nonspecialist readers.

- **Concern ID** R1-m2  
- **Severity** Minor  
- **Axis** Scientific importance  
- **Affected element** Conclusion  
- **Evidence pointer** Abstract, location not provided  
- **Issue** The statement that the compounds "can take place in cancer drug research" is speculative and not supported by any biological data (e.g., cytotoxicity, cellular uptake, or selectivity assays).  
- **Required correction** Soften the claim to indicate that the compounds warrant further investigation, or provide preliminary biological data to support the statement.

- **Concern ID** R1-m3  
- **Severity** Minor  
- **Axis** Technical soundness  
- **Affected element** Calibration equations  
- **Evidence pointer** Abstract, location not provided  
- **Issue** The abstract mentions calibration equations and correlation coefficients (r^2) but does not report the values or the range of concentrations used.  
- **Required correction** Report the calibration equation parameters and r^2 values, or state that these are provided in the full manuscript.

## Risk / unsupported claims
- The claim that the compounds bind to DNA via groove binding mode is unsupported from the abstract alone, as no quantitative data or controls are provided.
- The claim that compound B shows the best DNA binding activity is not verifiable without error estimates for the binding constants and details of the docking methodology.
- The suggestion that the compounds can be used in cancer drug research is unsupported by any biological or functional data.
- The structural characterization claims (FT-IR, NMR, UV-vis, photoluminescence, X-ray crystallography) are not verifiable from the abstract, as no spectra or crystallographic parameters are provided.